HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Expectation of drug shortages has become ‘new norm’ for cancer care
• Clinicians must educate patients about risks, benefits of surgical treatments for early breast cancer E. Shelley Hwang, MD, MPH
• Novel oral anticoagulants ‘not devoid of downsides’ Ido Weinberg, MD
• Déjà vu all over again — or am I missing the take-home message? John Sweetenham, MD, FRCP, FACP
• FDA approves Lynparza, companion diagnostic for advanced ovarian cancer
• FDA approves edoxaban to reduce stroke risk, treat DVT and PE
• FDA approves Granix injection for self-administration in patients with severe neutropenia
• FDA grants fast track status to IMMU-132 for triple-negative breast cancer
• FDA approves Opdivo for treatment of advanced melanoma
• Sunitinib appeared active in meningioma
• Bisphosphonate prescriptions low among men who underwent ADT
• Childhood, adolescent cancer survivors at increased risk for hospitalization
• Panobinostat regimen extended PFS in multiple myeloma
• Study reveals ‘concerning’ increase in colorectal cancer incidence among young adults
• Gleason score associated with time to development of neuroendocrine prostate cancer
• Somatic mutations linked to malignant transformation of aplastic anemia
• Acid reflux medications may extend survival in HNSCC
• ACS: More than 1.5 million cancer deaths averted since 1991
• ADT raised risk for cardiac death in men with prostate cancer
• Allogeneic transplantation achieved graft-versus-myeloma effect
• Bevacizumab not significantly associated with VTE risk in patients with prostate cancer
• FDA panel casts ‘historic’ vote in support of biosimilar filgrastim
• Immediate chemotherapy after radical cystectomy failed to extend OS
• Ipilimumab demonstrates long-term survival benefit in advanced melanoma
• More studies urged in managing posttreatment fatigue in thyroid cancer
• Nearly one-third of AYA patients do not receive adequate cancer therapy
• Nitrogenous bisphosphonate use may reduce risk for endometrial cancer
• Nivolumab showed antitumor activity in patients with metastatic renal cell carcinoma
• Noninvasive tool identified high coronary artery disease burden in childhood cancer survivors
• Para-aortic irradiation increased diabetes risk in long-term survivors of Hodgkin’s lymphoma
• Pediatric patients with sickle cell disease showed moderate medication adherence
• Primary tumor resection extended survival in unresectable synchronous metastases from CRC
• Prolonged surgery increased risk for VTE
• Prophylactic cranial irradiation effective for stage IIIA-N2 NSCLC
• Radiotherapy, surgery conferred similar survival in cervical esophageal cancers
• RAS mutations predicted metastatic spread, survival in colorectal cancer
• Upfront laryngectomy may improve survival in advanced-stage laryngeal cancer
• Use of bilateral mastectomy increased significantly despite lack of mortality benefit
• Bisphosphonates may reduce risk for bone metastases in women with breast cancer
• Olaparib induced tumor response in patients with germline BRCA1/BRCA2 mutations
• Trastuzumab plus adjuvant chemotherapy improved OS, DFS in HER-2–positive positive breast cancer
• One-fourth of patients who undergo breast conservation surgery required additional surgery
• Cancer institute appoints new CEO
• Foundation honors young investigators
• NY Presbyterian appoints director of experimental therapeutics
• Professor to join Rice University
• Roswell Park Cancer Institute names chief quality officer
• ASH 2014: Diving for pearls in a massive sea of presentations Harry S. Jacob, MD, DHC
• Bevacizumab plus FOLFOXIRI extended OS in advanced colorectal cancer
• ENGAGE AF-TIMI 48: Edoxaban dose reduction improved clinical outcomes
• High vitamin D levels linked to improved outcomes in metastatic colorectal cancer
• Ramucirumab combination benefited patients with advanced colorectal cancer